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Cetuximab remains to date the only targeted therapy approved for the treatment of head
and neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the
tumorigenesis and progression of this disease as well as in the resistance to radiotherapy
(RT). While several anti-EGFR agents have been tested in HNSCC, cetuximab, an IgG1
subclass monoclonal antibody against EGFR, is the only drug with proven efficacy
for the treatment of both locoregionally-advanced (LA) and recurrent/metastatic (R/M)
disease. The addition of cetuximab to radiotherapy is a validated treatment option in
LA-HNSCC. However, its use has been limited to patients who are considered unfit for
standard of care chemoradiotherapy (CRT) with single agent cisplatin given the lack of
direct comparison of these two regimens in randomized phase III trials and the inferiority
suggested by metanalysis and phase II studies. The current use of cetuximab in HNSCC
is about to change given the recent results from randomized prospective clinical trials in
both the LA and R/M setting. Two phase III studies evaluating RT-cetuximab vs. CRT
in Human Papillomavirus (HPV)-positive LA oropharyngeal squamous cell carcinoma
(De-ESCALaTE and RTOG 1016) showed inferior overall survival and progression-free
survival for RT-cetuximab combination, and therefore CRT with cisplatin remains the
standard of care in this disease. In the R/M HNSCC, the EXTREME regimen has been
the standard of care as first-line treatment for the past 10 years. However, the results
from the KEYNOTE-048 study will likely position the anti-PD-1 agent pembrolizumab
as the new first line treatment either alone or in combination with chemotherapy in
this setting based on PD-L1 status. Interestingly, cetuximab-mediated immunogenicity
through antibody dependent cell cytotoxicity (ADCC) has encouraged the evaluation of
combined approaches with immune-checkpoint inhibitors in both LA and R/M-HNSCC
settings. This article reviews the accumulated evidence on the role of cetuximab in
HNSCC in the past decade, offering an overview of its current impact in the treatment of
LA and R/M-HNSCC disease and its potential use in the era of immunotherapy.
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INTRODUCTION
The role of the epidermal growth factor receptor (EGFR) in
the development and progression of head and neck squamous
cell carcinoma (HNSCC) has been widely studied (1). EGFR is
a transmembrane glycoprotein member of the tyrosine kinase
growth factor receptor family that regulates cell growth and
proliferation (2). This receptor is overexpressed in up to 90%
of HNSCC and has been associated with decreased survival (2–
4). The accumulating evidence led to the evaluation of agents
targeting the EGFR pathway in this tumor type.
Cetuximab is the only anti-EGFR agent that has been
proven effective for the treatment of HNSCC thus far (5, 6).
Cetuximab is a chimeric IgG1-subclass monoclonal antibody
that binds to the extracellular domain of the EGFR with higher
affinity than the natural ligands EGF and TGFα, blocking the
activation of its intracellular domain and subsequent tyrosine
kinase-dependent signal transduction pathway (7). Cetuximab
also stimulates the internalization of EGFR, removing the
receptor from the cell surface and thus preventing its interaction
with the ligand (8). Additionally, as an IgG1 molecule, it
stimulates antibody dependent cell cytotoxicity (ADCC) (9, 10).
Several preclinical studies demonstrated that EGFR inhibition
by cetuximab increases the efficacy of radiotherapy (RT) (11)
since it decreases the proportion of cells in S phase and increases
that of G1 phase, facilitates apoptosis, decreases the capacity
of DNA repair, and has an antiangiogenic effect (12, 13).
Moreover, cetuximab enhanced the antitumor activity of several
chemotherapeutic drugs in mouse xenograft models (14).
Cetuximab reached the clinics a decade ago at a time where
treatment options for HNSCC were very limited. Chemo-RT
(CRT) or RT alone depending on patients’ functional status and
comorbidities were the only available conservative treatment
options in the locally-advanced (LA) setting. Cetuximab
improved the variability of choice (5) although the clinical
practice finally positioned its use in combination with RT (RT-
Cx) to those patients unfit to receive high dose cisplatin or
those who had previously received three cycles of cisplatin-
based induction chemotherapy (ICT) and had significant residual
toxicity. In recurrent/metastatic (R/M) HNSCC, we had to
choose between monotherapy and polychemotherapy until the
results from the EXTREME trial. The addition of cetuximab to
first-line chemotherapy significantly improved disease control
and overall survival (OS) when compared to chemotherapy alone
becoming the new standard of care in this patient population
(6). However, despite the EXTREME regimen has remained the
recommended first-line as per the clinical guidelines for the past
10 years, its use has been limited outside Europe. Nevertheless,
the results of the KEYNOTE-048 clinical trial (NCT02358031)
evaluating the activity of pembrolizumab (anti-PD-1 therapy)
with or without chemotherapy will likely lead immunotherapy
to the first line treatment for the majority of R/M HNSCC
patients (15).
Besides cetuximab, several anti-EGFR monoclonal antibodies
have been tested in HNSCC, including panitumumab,
zalutumumab and nimozutumab (1, 16–18). Among all
these, panitumumab is the only one that has been evaluated in
randomized phase III clinical trials in both LA and R/M disease,
failing to show any improvement in LRC or survival when
compared to the standard of care (16, 19). Some authors argued
that, unlike cetuximab (IgG1), the inability of panitumumab
(IgG2) to produce antitumor activity through ADCC and natural
killer (NK) cell activation might have explained the lack of
benefit from this agent in HNSCC (7, 20). To date, cetuximab is
the only anti-EGFR antibody with proven efficacy and survival
gain in HNSCC.
In this article, the authors review the evidence accumulated on
the role of cetuximab in HNSCC in the past decade, offering an
overview of its current impact in the treatment of LA and R/M
disease and its potential use in the era of immunotherapy.
LOCALLY-ADVANCED HEAD AND NECK
SQUAMOUS CELL CARCINOMA
Has Cetuximab Reached a Plateau in the
Treatment of LA-HNSCC?
Cetuximab is the only targeted therapy that has been
proven effective for the treatment of LA-HNSCC (5). The
implications of EGFR overexpression in resistance to RT has
been reported in several studies (2, 13). Preclinical models
showed that EGFR blockade by cetuximab increases radiation-
induced apoptosis and blocks secondary repair mechanisms
dependent on PI3K/AKT/MAPK and JAK/STAT3 downstream
signaling pathways, indicating a synergistic effect of the RT-Cx
combination (21, 22). In 2006, the Bonner randomized phase
III study evaluated the addition of cetuximab to RT in over 400
patients with LA-HNSCC showing a significant improvement
in locoregional control (LRC) (24.4 vs. 14.9 months, p = 0.005)
and OS (49 vs. 29 months, p = 0.006) with the combination
(5). These results led to the FDA approval of cetuximab for
the treatment of LA-HNSCC and RT-Cx was incorporated in
the clinical guidelines as a validated alternative to standard
chemoradiotherapy (CRT) in this setting (23, 24).
The survival benefit obtained by the addition of cetuximab
to RT was confirmed by the 5-year update of the Bonner trial
(5-year OS of 45.6% for the combination vs. 36.4% for RT
alone, p = 0.018). However, the lack of a direct comparison
with standard of care CRT in randomized phase III trials
and the differential toxicity profile of both drugs contributed
to limit the use of RT-Cx to patients considered “unfit” for
cisplatin-based CRT despite this patient population was not
represented in the Bonner trial (25, 26).Whether both treatments
are equivalent in terms of efficacy has remained unclear over
the years as several retrospective series and meta-analysis had
showed mixed results (27–30). The meta-analysis conducted
by Huang et colleagues in 2016 including up to 31 studies
and over 4,000 patients showed no differences in disease
control or survival beyond the 2-year threshold between both
treatment combinations, although the overall pooled HR for
OS, progression-free survival (PFS) and LRC were significantly
inferior in the arm of RT-Cx (31). However, the intrinsic
limitations of the retrospective analyses including unmatched
patient characteristics and biased treatment selection based on
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patient’s baseline condition difficulted the interpretation of these
data. The prospective randomized phase II trial evaluating CRT
vs. RT-Cx conducted by Magrini et al. failed to show any
significant differences in treatment outcome between both arms,
despite the 2-year LRC and 2-year cancer specific survival rates
were lower among patients treated with RT-Cx (53 vs. 80%;
and 68 vs. 81%, respectively) (32). Since the study was stopped
prematurely, with only 35 patients per arm, it was underpowered
for its primary endpoint, hence definitive conclusions could not
be drawn from its results. In HPV-positive LA oropharyngeal
cancer (OPC), two randomized phase III studies evaluating RT-
Cx vs. CRT (CDDP) in HPV-positive LA-OPC (De-ESCALAaTE
and RTOG 1016) have recently reported significantly worse
survival and disease control rates in the RT-Cx arm (33, 34).
A phase III randomized prospective study comparing RT-
Cx vs. CRT in LA-HNSCC with OS as primary endpoint
is currently on-going and might provide a more definitive
answer (NCT01969877).
The positive results obtained by the addition of cetuximab
to platinum-based chemotherapy in the first line R/M HNSCC
led to its evaluation in combination with CRT and ICT in
the LA setting (35–39). Few publications have reviewed the
studies conducted to date indicating that intensification therapy
with cetuximab given concurrently with CRT does not seem to
improve patient outcome but adds significant toxicity (1, 40, 41).
The only phase III randomized trial evaluating cetuximab plus
standard CRT with single agent cisplatin vs. CRT failed to show
any improvement in LRC, distant control nor survival in the
cetuximab arm but did show higher rate of grade 3/4 toxicity (36).
Recently, the GORTEC 2007-01 phase III study that evaluated
RT-Cx plus carboplatin and 5-FU vs. RT-Cx alone showed no OS
benefit despite better PFS and LRC, with again significantly grade
3–4 toxicity increment (42).
The addition of cetuximab to different ICT regimens appeared
to improve response rates and extend survival when compared to
historical controls, especially when combined with taxane-based
chemotherapy regimens (43–45). The role of ICT in LA-HNSCC
has been widely debated since it has not demonstrated a sustained
survival benefit when compared to standard CRT in randomized
trials (44, 46–49). Overall, the lack of control arms allowing
direct comparison in the studies evaluating cetuximab-based ICT
combinations and the severe toxicity increased in some of the
trials, particularly when using the TPF regimen, has precluded
a widespread use of this treatment modality among the head and
neck community (49–51). However, RT-Cx given sequentially to
ICT does seem to offer similar results in terms of efficacy when
compared to standard CRT, with an overall acceptable toxicity,
which is particularly relevant in patients who previously received
cisplatin as part of the ICT (37, 39, 52, 53).
To date, no randomized phase III trials have evaluated
the role of cetuximab vs. cisplatin in the adjuvant treatment
of resected LA-HNSCC. The phase II study RTOG-0234 did
investigate the addition of cetuximab to weekly docetaxel or
cisplatin and RT in patients with resected HNSCC and high
risk features (positive margins and/or extranodal extension) (54).
Despite both regimens were tolerable, and the combination with
docetaxel showed promising disease-free survival, these regimens
were never compared against standard post-operative high-dose
cisplatin and RT in a randomized study, and therefore its use
was not widespread. Similarly, the ACCRA-HN phase 2 study
compared post-operative RT-Cx vs. RT-Cx plus cisplatin and
5-FU (NCT00791141), although the results of these study have
not been published yet.
Overall, with the current available data, RT-Cx remains a
valid treatment option for the treatment of LA-HNSCC, although
standard of care CRT (cisplatin 100mg/m2 every 3 weeks) should
be pursued when feasible. Sequential RT-Cx following ICT as part
of organ-preservation strategy is a reasonable alternative to avoid
acute and late toxicity, but other treatment combinations should
be avoided. There is no evidence to support the use of cetuximab
in the adjuvant setting.
Other Cetuximab Containing Combinations
in LA-HNSCC
Cetuximab has also been investigated in combination with a
variety of chemotherapy agents and targeted therapies inmultiple
clinical trials for LA-HNSCC although none of them has reached
the clinics yet. Based on the good results observed in combination
with taxanes in the R/M setting and within ICT regimens in
the LA disease above mentioned, a few trials evaluated the
combination of cetuximab with taxanes concurrent with RT.
A phase I/II study investigated nab-paclitaxel plus cetuximab
and low-dose cisplatin (20 mg/m2) showing similar 2-year PFS
compared to historical controls (60%) and tolerable toxicity, but
no further evaluation of this regimen is on-going (55). A separate
phase II randomized study is evaluating docetaxel plus cetuximab
concurrent with RT vs. standard CRT, but results are yet to be
presented (NCT02128906). Other chemotherapy combinations,
such as pemetrexed plus cetuximab and RT have also been tested
in phase II studies with similar efficacy and tolerability, but have
not been further investigated in phase III randomized trials (56).
In regards to targeted therapies, Bevacizumab, an anti-VEGF
monoclonal antibody, has been investigated in combination
with cetuximab in the LA-HNSCC based on preclinical data
suggesting a key role for VEGF pathway in the resistance to
RT and Cetuximab (57, 58). Given the promising activity and
tolerability seen in early studies performed in the R/M setting,
two phase II studies evaluated bevacizumab in combination with
RT plus pemetrexed and RT plus cisplatin (59, 60). Despite
positive results in terms of efficacy, the increased toxicity and
the lack of comparative arms precluded further investigation of
bevacizumab in this setting. Other antiangiogenic agents, such as
sunitinib, have been combined with cetuximab (NCT00906360)
but results are still pending.
The inhibition of other molecular targets including the
Src family kinase, the Poly (ADP-Ribose) Polymerase (PARP),
Cyclin Dependent Kinase complex (CDK) has shown to have
a synergistic effect in combination with EGFR blockade by
cetuximab and overcome resistance to this agent according to
several studies using preclinical models (61–64). Dasatinib (SRC
inhibitor), olaparib (PARP inhibitor), and pablociclib (selective
CDK 4/6 Inhibitors) are currently subject of investigation
in combination with cetuximab and RT in the LA setting
(NCT00882583, NCT01758731, NCT03024489, respectively).
Despite preliminary results from early trials have showed a safe
toxicity profile with the combination, their efficacy is yet to
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be determined (65, 66). Noteworthy, preclinical studies using
xenograft models suggested that dasatinib might be detrimental
for tumor control when combined with cetuximab and RT (61).
Therefore, we must remain cautious while awaiting the results
from the ongoing clinical trials.
A summary of published phase II/III studies evaluating
cetuximab combinations in LA-HNSCC is provided
(Supplementary Table 1).
Patient Selection: Are the Bonner Trial
Results Reproducible in Daily Practice?
Besides the severity of cetuximab-induced skin rash no other
biomarkers have shown to predict clinical activity of cetuximab
(67). Several biological and molecular candidates have been
tested including EGFR protein expression, truncated receptor
variants, such as EGFRvIII, or mutations at the level of EGFR
gene or downstream, such as KRAS, but thus far none of them
has been proven effective in predicting response (or resistance)
to cetuximab in HNSCC (68–71). Therefore, treatment selection
between standard CRT and RT-Cx in patients with LA-
HNSCC has been often based on patient baseline condition and
comorbidities, taking into consideration the differential toxicity
profile between cetuximab and cisplatin. Patients with significant
comorbidities and/or poor ECOG performance status and the
elderly are usually ineligible for cisplatin and as such, they tend
to be treated with cetuximab (72). Cetuximab’s acute side effects
mainly include infusion reactions, skin rash and mucositis, with
no major organ-specific or chronic toxicity described, making
it a suitable option for this patient population (29). However,
the majority of patients enrolled in the Bonner study were
under 70 years old, with no significant comorbidities and a
Karnofsky index ≥80 (5). In this regard, an exploratory post-
hoc analysis published in the 5-year update of the Bonner trial
suggested that younger patients with good performance status
were more likely to benefit from this combination (25). Several
studies have reported increased risk of local and systemic toxicity
from cetuximab in patients at older age, with significant baseline
comorbidities or with poor performance status, including
cytopenia, bloodstream infections and sepsis (73). Some authors
have postulated that fragile patients might be more susceptible
to toxicity due to local and systemic inflammatory responses
triggered by cetuximab-induced antibody-dependent cellular
cytotoxicity (74).
Altogether these data suggest that the expected efficacy and
toxicity from RT-Cx might differ when compared to the Bonner
trial in our daily practice given our biased patient selection for
this treatment. Hence, the need for prospective trials focusing on
this frail population is timely.
RECURRENT OR METASTATIC HEAD AND
NECK SQUAMOUS CELL CARCINOMA
Cetuximab in R/M HNSCC
In 2006, a phase I/II study investigating cetuximab in
combination with cisplatin/carboplatin and 5-FU in R/M
HNSCC showed promising activity and acceptable tolerability
(75). The subsequent phase III randomized study evaluating
the addition of cetuximab to cisplatin/carboplatin and 5-FU
for a total of 6 cycles followed by maintenance cetuximab
(EXTREME regimen) vs. chemotherapy alone in the first-
line R/M setting conducted by Vermorken and colleagues
demonstrated the superiority of the combination in terms of
OS and response rate (6). The combined regimen improved
both OS and PFS from 7.4 to 10.1 months; and from 3.3 to 5.6
months, respectively, when compared to chemotherapy alone.
The overall response rate (ORR) was also increased from 20 to
36% with the combination. The most common grade 3 or 4
adverse events in the chemotherapy-alone and cetuximab groups
were anemia (19 and 13%, respectively), neutropenia (23 and
22%), and thrombocytopenia (11% in both groups). Of 219
patients receiving cetuximab, 9% had grade 3 skin reactions (6).
The results from this study set the EXTREME regimen as the
new standard of care for the first-line treatment of R/M HNSCC
(24, 76), which has remained unchanged since 2008. Noteworthy,
subsequent observational studies (SOCCER, DIRECT, ENCORE)
endorsed the results from the EXTREME study in the daily
clinical practice (76–78). In addition, about 14% of the patients
treated with the EXTREME regimen have been reported to have
long-term responses (35).
Several randomized trials are currently evaluating immune-
checkpoint inhibitors (ICI) alone or in combination with
chemotherapy against the EXTREME regimen in an attempt
to improve patients’ survival and quality of life. The
main phase III randomized clinical trials are keynote-048
(NCT02358031), Kestrel (NCT02551159), and Checkmate-651
(NCT02741570) (Figure 1).
The preliminary results of the Keynote 048 trial have been
recently presented. This phase III study evaluated the efficacy
of pembrolizumab (anti-PD-1) alone and in combination with
cisplatin/carboplatin plus 5FU vs. the EXTREME regimen as
first-line therapy for R/M-HNSCC based on PD-L1 expression
by CPS (combined positive score) (15). The study showed better
OS in the pembrolizumab monotherapy arm vs. EXTREME
when PD-L1 expression ≥1 and ≥20% by CPS (HR 0.78
[0.64–0.96], p = 0.0086 and HR 0.61 [0.45–0.83], p = 0007,
respectively) and in the pembrolizumab plus chemotherapy
arm vs. EXTREME regardless of PD-L1 expression (10.7 vs. 13
months, HR 0.77 IC 95% 0.63–0.93, p = 0.0034). With these
results, pembrolizumab monotherapy and the combination of
pembrolizumab-chemotherapy will likely become the new first
line treatment for R/M-HNSCC based on CPS PD-L1 expression.
However, the complete results of the study are still to be
published, and full biomarker analyses are awaited.
Improving the EXTREME Regimen With
Other Chemotherapy Agents
Within the 3 drugs of the EXTREME regimen, 5-FU is the most
difficult one to be administered in terms of logistics, as it requires
24-h continuous infusion for a total of 4 days. Furthermore, 5-FU
is associated with increased rate of mucositis and diarrhea, and its
use is not recommended in patients with cardiovascular diseases
or with dihydropyrimidine dehydrogenase deficiency. Therefore,
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FIGURE 1 | Main clinical trials evaluating the efficacy of new schemes of treatments compared with the EXTREME regimen.
the substitution of 5-FU with a taxane is being investigated
as a potentially new scheme for R/M-HNSCC. Preclinical data
have suggested a synergistic effect when combining taxanes
with cetuximab (79). Bossi et al. demonstrated in a phase
IIb clinical trial (B409) that the cetuximab-cisplatin regimen
was non-inferior to the cetuximab-cisplatin-paclitaxel regimen
in terms of PFS [HR for cetuximab-cisplatin vs. cetuximab-
cisplatin-paclitaxel [0.99; 95%CI: 0.72–1.36, P= 0.906; margin of
non-inferiority (90% CI of 1.4) not reached] (80). Interestingly,
the ORR achieved by the three drugs regimen was >50%.
Grade 4 toxicities were reported in 14% of patients receiving
cetuximab-cisplatin and 33% of those receiving cetuximab-
cisplatin-paclitaxel (P = 0.015), but by substituting 5-FU for
paclitaxel, the rates of grade_3 cardiac toxicity appeared lower in
both arms and no sepsis was described compared to EXTREME
regimen (80). Argiris et al. introduced for the first time the
combination of cisplatin-docetaxel-cetuximab in a phase II
clinical trial for LA-HNSCC (81). The GORTEC group developed
this combination (named “TPEx”) in a phase II study (GORTEC
2008-03) for R/M disease (82). They demonstrated that 4 cycles
of docetaxel combined with cisplatin (75 mg/m2 both at day 1)
and weekly cetuximab (250 mg/m2) followed by maintenance
cetuximab (500 mg/m2, every 2 weeks) were feasible, active, and
with a manageable safety profile in fit patients with R/MHNSCC.
ORR at week 12 was 44.4%; median OS and PFS were 14.0
and 6.2 months, respectively. In addition, the ORR increased to,
16.8 and 7.1 months in the population of patients with disease
control after the initial 4 cycles of complete TPEx regimen. The
European TPEx randomized phase II study evaluating the TPEx
regimen vs. the EXTREME regimen is currently ongoing and will
contribute in determining which one might be the best treatment
option for the first-line treatment in this patient population
(NCT02268695). Other taxane-based combinations in first-line
R/M-HNSCC are also being currently evaluated, such as the
phase II study CACTUX trial investigating nab-paclitaxel and
cetuximab (NCT02270814).
From the Clinical Trial to an Outpatient
Clinic: Treatment for Unfit Patients.
In daily clinical practice, a considerable number of patients
with HNSCC have significant comorbidities and/or a frail
functional status that makes them unfit to receive the EXTREME
regimen. This patient population is usually underrepresented
in clinical trials. Despite the lack of prospective randomized
data, the combination of taxanes with cetuximab or a
single agent (paclitaxel, docetaxel, cetuximab, methotrexate,
5-FU, capecitabine. . . ) have been suggested as alternative
treatment options for these patients. (83). The combination
of docetaxel/paclitaxel with cetuximab appears to have a
manageable safety profile and good response rates. Few
prospective single-arm phase II studies have investigated this
combination: the first study was conducted by Hitt et al.
and evaluated cetuximab plus paclitaxel as first-line treatment
showing an ORR of 54% (95% CI: 39–69) (84). Interestingly,
61% of the population included in the trial had a Karnofky
Index of 70–80%. The Knoedler et al. study evaluated cetuximab
plus docetaxel in patients who failed a platinum-based therapy,
achieving an overall disease control rate of 51% (85). Recently,
a retrospective study showed that the combination of paclitaxel
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and cetuximab could be a suitable treatment option in HNSCC
patients with platinum-based CRT-refractory disease (86).
In addition, based on the keynote 048 preliminary results
(15), pembrolizumab monotherapy might represent an option in
patients unfit for cisplatin-based chemotherapy.
Cetuximab Containing Combinations in
R/M HNSCC
The combination of cetuximab with different chemotherapy
regimens and with other targeted agents against key pathways
involved in HNSCC tumorigenesis and progression has been
investigated in several clinical trials.
Besides the EXTREME regimen and taxane-based
chemotherapy combinations, cetuximab has been also been
evaluated in combination with other chemotherapies, such
as pemetrexed or methotrexate. A phase III study comparing
pemetrexed plus cisplatin vs. cisplatin alone in R/M HNSCC
did not significantly improve survival for the intent-to-treat
population (87). Despite this result, a phase II study evaluated
the addition of cetuximab to this regimen. However, the study
did not reach its primary end-point (PFS) and was considered
negative (88). The Dutch Head and Neck Society is currently
investigating cetuximab in combination with methotrexate in a
Phase Ib-II study (NCT02054442).
Phosphatidylinositol 3-kinase (PI3-K) inhibitors were one
of the most promising targeted therapies for cetuximab-based
combinations given the relevance of the PI3K pathway in
proliferation, apoptosis and cell differentiation of HNSCC.
Two phase Ib/II studies are investigating the combinations
of cetuximab and PI3K inhibitors, the first one with BKM
120 (NCT01816984), and the second one with BYL719
(NCT01602315). A randomized phase II study evaluated the
addition of PX-866 to cetuximab in patients with advanced
R/M-HNSCC; PX-866 addition did not show any significant
improvement in PFS nor OS (89).
Cilengitide, an integrin inhibitor, has also been investigated
in the ADVANTAGE phase I/II study. The phase II part was
a multicenter, open-label, randomized and controlled study
investigating cilengitide 2,000mg once or twice weekly plus
chemotherapy based on EXTREME regimen vs. EXTREME
regime alone. Neither of the cilengitide-containing regimens
demonstrated a PFS benefit over EXTREME regimen alone in
R/M-SCCHN patients (90).
Preclinical studies had also suggested that mammalian
target of rapamycin (mTOR) inhibitors might overcome the
resistance to EGFR blockade and augment cetuximab efficacy.
The combination of everolimus (RAD001) with cetuximab and
carboplatin was explored in a phase I study showing encouraging
antitumor activity in a selected group of patients (91). The
currently on-going MAESTRO study is evaluating temsirolimus
with or without cetuximab for previously treated R/M-HNSCC
patient (NCT01256385).
Based on pre-clinical data, Argiris et al. conducted a phase II
study to evaluate the efficacy of bevacizumab and cetuximab in
patients with R/M SCCHN refractory to first-line treatment. The
modest median PFS and OS (2.8 and 7.5 months, respectively)
did no lead to further development of this regimen (59).
Other agents, such as patritumab (U3-1287), an anti-HER3
monoclonal antibody, in combination with platinum-based
therapy and cetuximab has been studied in a double-blind phase
2 study, but no results have been released yet (NCT02633800).
Cyclin-dependent-kinase-inhibitors, such as palbociclib are also
been tested in combination with avelumab and cetuximab for
R/M-HNSCC (NCT03498378).
A summary of published phase II/III studies evaluating
cetuximab combinations in RM-HNSCC is provided
(Supplementary Table 2).
CETUXIMAB IN HPV-POSITIVE OPC
HPV-positive OPC represents a biologically distinct disease
characterized by increased radiosensitivity and improved overall
survival when compared to HPV-negative OPC (92, 93).
Retrospective subgroup analyses from randomized trials had
reported better outcome in patients with HPV-positive disease,
regardless of treatment (94–96). Given the acute and potential
long-term side-effects associated to CRT (97), many on-going
clinical trials are currently evaluating de-escalation treatment
strategies to reduce long-term toxicity without compromising
survival in this subgroup of patients (98). Chemo-sparing
approaches to replace cisplatin by other agents, such as cetuximab
or immune checkpoint inhibitors (ICI) given concurrent with
radiation are the most attractive options (NCT02254278,
NCT01874171, NCT03410615). Main de-escalation clinical trials
ongoing evaluating cetuximab in combination with RT are
summarized on Table 1.
TABLE 1 | Main de-escalation clinical trials ongoing evaluating cetuximab in combination with RT for HPV-related OPSCC.









Phase III 987 p16INK4a IHC OS (non-inferiority) Cisplatin day 1 and 22
Australia TROG 1201
NCT01855451




Phase III 334 p16INK4a IHC Overall severe (acute and
late) toxicity (Grade 3–5)
Cisplatin day 1, 22, and 43
Bulky disease with >10 p/y
smoking history excluded
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The role of cetuximab in HPV-positive OPC has been
extensively debated (99, 100). The exploratory subgroup analysis
from the 5-year survival update of the Bonner study seemed to
favor the use of cetuximab in young patients (<65 years old),
with primary OPC and high Karnofsky index (25). The post-hoc
analysis published by Rosenthal et al. evaluating the differential
effect of RT-Cx in p16-positive vs. p16-negative patients treated
within the Bonner trial showed higher OS gain in the p16-
positive subgroup (HR 0.38 vs. 0.93, respectively) (101). However,
no significant interaction was observed between p16 positivity
and treatment effect. Similarly, the exploratory subgroup analysis
from the EXTREME trial in the recurrent/metastatic setting
reported increased survival in HPV-positive vs. HPV-negative
patients (102). Conversely, in the CONCERT-2 and SPECTRUM
clinical trials evaluating panitumumab in the LA and R/M
setting, respectively, patients with p16-positive tumors had
significantly lower survival when compared to p16-negative
disease (16, 45). The fact that both studies were negative
for their primary endpoints and that the threshold used for
p16 positivity was lower than the standard recommendations
(10% staining instead of 70%) made interpretation of these
results difficult.
The accumulating evidence on the biological rationale
behind the use of cetuximab in HPV-positive disease had
been inconsistent with the abovementioned subgroup analysis.
Several studies had highlighted the absence of EGFR protein
overexpression and EGFR/HER pathway activation in HPV-
driven tumors (103–106). Moreover, a comprehensive analysis of
the genomic landscapes of HPV-positive and negative HNSCC
confirmed the lack of EGFR aberrations in HPV-positive tumors
and an increased frequency of RAS mutations when compared
to HPV-negative tumors (107). Noteworthy, anti-EGFR therapies
are not currently recommended for treatment of anogenital
HPV-positive cancer (108, 109) highlighting the lack of sense of
targeting EGFR in HPV-related tumors.
In concordance with these data, latter studies did show
decreased efficacy of RT-Cx in HPV-positive disease (27, 110).
The interim subgroup analysis from a prospective phase II
trial evaluating RT-cetuximab vs. CRT with weekly cisplatin
in LA-HNSCC showed a trend favoring the cisplatin arm
TABLE 2 | Summarized of clinical data investigating anti-EGFR therapy on HPV-positive HNSCC.
References (Study) Treatment HPV positivity analysis Result
Recurrent and metastatic HNSCC
Vermorken et al. (45)
(SPECTRUM)
Cisplatin and fluorouracil ±
panitumumab
Prospective Addition of panitumumab to cisplatin-based
chemotherapy significantly improves OS and PFS only in
HPV negative HNSCC patients
Vermorken et al. (90)
(EXTREME)
Cisplatin and fluorouracil ±
cetuximab
Retrospective Survival benefit of adding cetuximab to platinum-based
chemotherapy was independent of p16 status




Prospective HPV-negative HNSCC but not HPV-positive are most
likely to respond to EGFR blockage by cetuximab or
duligotuzumab.
Seiwert et al. (112)
(BIBW 2992 trial)
Afatinib vs. cetuximab Prospective HPV positive HNSCC patients had a lower response rate
to EGFR inhibitors compared with HPV negative patients
Locally advanced HNSCC




Retrospective series p16-positive patients may benefit more from RT
combined with EGFR inhibitors than with cisplatin




Retrospective series Treatment with cisplatin not cetuximab predict for better
OS, FFS and locoregional control
Ang et al. (36)
(RTOG 0522 study)
Cisplatin ± cetuximab with
AFX RT
Prospective The addition of cetuximab produce no benefit in PFS or
OS in patient with p16 positive or negative HNSCC
Rosenthal et al. (101)
(IMCL-9815 phase III Study)
RT vs. cetuximab-RT Retrospective Better outcomes in both groups p16-positive and
p16-negative when treated with cetuximab and RT in
comparison with RT alone




Prospective No benefit was noted with the addition of panitumumab
in either PFS or OS in the patients with p16-postive
tumors




Prospective Better outcomes for cisplatin-RT (few p16 positive
patients included)




Restrospective series Better outcomes in patients receiving concurrent
cisplatin over cetuximab regardless of HPV/p16 status





Retrospective series Improved OS for all treatment schemes with the
exception of those who underwent cetuximab-RT
AFX RT, Accelerated fractionation radiotherapy; HNSCC, Head and neck squamous cell carcinoma; FFS, failure free survival; OS, overall survival; PFS, progression free survival;
RT, radiotherapy.
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in all outcome parameters including LRC, PFS and OS in
the p16-positive group (NCT01216020) (110). Unfortunately,
this study was terminated due to slow recruitment and the
sample was limited and therefore unpowered to show significant
differences. Summarized clinical data investigating anti-EGFR
therapies on HPV-positive OPC are presented on Table 2. It
is important to highlight that most of these studies based
the HPV positivity on p16 staining exclusively. Recently
published data suggest that p16 expression alone may not be
accurate to classify OPC as HPV-positive, and other biomarkers,
such as HPV DNA might be required to characterize these
tumors (117–119).
The results from three de-escalation randomized phase III
clinical trials (Table 1) evaluating RT-Cx vs. standard CRT with
cisplatin provided a definitive answer regarding the role of
cetuximab in HPV-positive OPC patients. The RTOG 1016, a
phase III non-inferiority study showed inferior OS in the RT-
Cx arm [5 years OS 84.6 (95% CI 73.4–82.5) vs. 77.9% (95%
CI 73.4–82.5)] (34). The De-SCALaTE phase III clinical trial
revealed the same rate of severe and all-grade toxicities when
compared to CRT and worse OS in the RT-Cx arm (2 years OS
97.5 vs. 89.4%; HR = 4.99; 95% CI: 1.70–14.67 (33). Therefore,
CRT will remain the standard of care for HPV-positive LA-




The efficacy of cetuximab has been partly attributed to its
immunologic activity through ADCC, which is thought to
link innate and adaptive antitumor immune responses via
NK cells and antigen presenting cells that ultimately lead
to EGFR-specific T cells (120, 121). Long-term survivorship
described in patients with R/M HNSCC treated with cetuximab
might be explained by sustained antitumor specific immune
responses (122). The immunologic activity of cetuximab is
of relevance in the era of immunotherapy. ICI will shortly
become a backbone in the treatment of R/M HNSCC, and are
already being investigated in the LA setting in combination
with CRT or RT alone (NCT02952586, NCT03040999) (123,
124). Safety data from a phase I study combining ipilimumab
(anti-CTLA-4 monoclonal antibody) with cetuximab and IMRT
in LA-HNSCC (NCT01935921) was presented at ESMO
meeting in 2016 by Bauman et al. (125). While dermatologic
side-effects were the main dose-limiting toxicity of this
combination, they were manageable, and treatment was felt
to be overall well-tolerated. Results on efficacy are waiting.
Growing evidence supports the investigation of antiPD-1/PD-
L1 agents in combination with cetuximab and RT in LA-
HNSCC (126, 127). The immunostimulatory effects attributed
TABLE 3 | Main clinical trials evaluating cetuximab combinations with ICI in HNSCC.
N Treatment Phase/status Comments
LOCALLY-ADVANCED HNSCC
NCT02999087 688 Experimental arm: Avelumab +
cetuximab + IMRT
Phase III/recruiting Comparative arm: standard CRT with high
dose cisplatin D1,22,43
NCT03349710 1046 Cohort 1:
Experimental arm A: Nivolumab +
cetuximab/placebo + IMRT
Experimental arm B: Cetuximab +
nivolumab/placebo + IMRT
Phase III/recruiting Comparative double-blind, placebo-controlled,
Phase 3 study. The study includes a 2nd
cohort (cohort 2) with experimental arms C and
D involving cisplatin + nivolumab/placebo
NCT03051906 69 Experimental arm: Cetuximab +




Excludes oral cavity and HPV-positive
oropharynx when T1-2, N0-N2a (AJCC, 7th
ed.) or any T, any N with smoking history of
<10 pack/years




Safety data presented at ESMO 2016 (125).
R/M HNSCC
NCT02643550 100 Experimental arm: Monalizumab +
cetuximab
Phase Ib-II One arm for patients with prior exposure to
PD-(L)1 ICI




NCT03498378 24 Experimental arm: Avelumab +
cetuximab + palbociclib
Phase I
NCT00397384 83 Experimental arm: Pembrolizumab +
cetuximab




NCT01836029 175 Comparator arm:
EXTREME
Experimental arm: EXTREME +
motolimod (VTX-2337, TLR8)
Phase II Randomized
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to RT, the increased antitumor immune infiltration induced
by cetuximab and the blockade of inhibitory checkpoint
receptors by ICI are hypothesized to act in a synergistic
manner and ultimately revert the immune suppression of
the HNSCC tumor microenvironment. As such, this triple
combination is already being investigated in several clinical
trials with different anti-PD-1/PD-L1 agents including avelumab
(NCT02999087), durvalumab (NCT03051906) or nivolumab
(NCT03349710) (128).
In R/M HNSCC disease, ICI are also being investigated
in combination with cetuximab. Anti-PD-1, such as
pembrolizumab or anti-PD-L1, such as avelumab in combination
with cetuximab are being evaluated in phase II clinical
trials [NCT03082534 and REACH study (NCT03082534),
respectively]. Furthermore, preliminary data from an ongoing
Phase I/II trial evaluating the safety and efficacy of the
combination of monalizumab, a first-in-class monoclonal
antibody targeting NK checkpoint receptor NKG2A, with
cetuximab in previously treated R/M HNSCC patients reported
increased response rates with the combination without
potentiating the side effects of cetuximab (129).
Apart from ICI, other immunotherapies, such as motolimod
(VTX-2337), a Toll-like receptor 8 agonist, are being investigated
in combination with cetuximab (130) (NCT01836029). The
addition of motolimod to the EXTREME regimen has been
recently evaluated. Despite it was overall well-tolerated, it did
not improve survival. However, in the subgroup analysis, patients
with HPV-positive disease and those with injection site reactions
seemed to benefit from the combination, suggesting that TLR8
stimulation may be useful in biomarker-selected patients (131).
Main clinical trials evaluating cetuximab combinations with
ICI HNSCC are summarized on Table 3.
CONCLUSIONS
Cetuximab is the only targeted therapy that has been proven
effective for the treatment of HNSCC in both the LA and R/M
settings. The incorporation of cetuximab not only expanded
the range of treatment options in the past decade but also
encouraged the investigation of many other targeted therapies
in this tumor type. Particularly in LA-HNSCC, cetuximab has
been crucial for the treatment of a subset of patients unfit for
standard CRT due to baseline comorbidities or poor clinical
condition. Despite this population was under-represented in the
Bonner trial, RT-Cx has been the cornerstone in this subgroup
of patients given its superiority when compared to RT alone.
However, the lack of a direct comparison with CRT and the
absence of predictive biomarkers of response to cetuximab have
conditioned its widespread use in this setting. Results from the
on-going clinical trials will hopefully shed light into this matter.
In patients with HPV-positive OPC, the results from the RTOG-
1016 and De-ESCALaTE phase III clinical trials have confirmed
the inferiority of RT-Cx compared to standard CRT (cisplatin)
in this disease, indicating that cetuximab is not an equivalent
treatment option for de-escalation approaches in this patient
population. The EXTREME regimen has remained the standard
of care for the first line treatment of R/M-HNSCC in patients
with PS 0–1. However, its use was not widespread likely due to the
considerable toxicity and the logistics of managing 3 concomitant
drugs including 5-FU. In the light of the recent results from
the Keynote 048 study, the antiPD-1 agent pembrolizumab will
likely become the new standard either alone or in combination
with chemotherapy as first-line treatment for R/M HNSCC
based on CPS PD-L1 expression. On-going trials evaluating
cetuximab combinations with ICI and other immunotherapies
might offer soon new treatment options in both LA and
R/M HNSCC.
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